What is the Market's View on Titan Pharmaceuticals, Inc. common stock (TTNP) Stock's Price and Volume Trends Thursday?

Thursday, December 15, 2022 01:01 PM | InvestorsObserver Analysts

Mentioned in this article

What is the Market's View on Titan Pharmaceuticals, Inc. common stock (TTNP) Stock's Price and Volume Trends Thursday?

The market has been neutral on Titan Pharmaceuticals, Inc. common stock (TTNP) stock recently. TTNP gets a Neutral score from InvestorsObserver Stock Sentiment Indicator.

Titan Pharmaceuticals, Inc. common stock has a Neutral sentiment reading. Find out what this means for you and get the rest of the rankings on TTNP!

See Full TTNP Report

What is Stock Sentiment?

When making investment decisions, sentiment gives a good overview of what stocks investors currently favor. Sentiment incorporates short-term technical analysis into its score and does not encompass any fundamental analysis such as profitability of the company. This means that earnings updates and other news can greatly impact overall sentiment. Price action is generally the best indicator of sentiment. For a stock to go up, investors must feel good about it. Similarly, a stock that is in a downtrend must be out of favor. InvestorsObserver’s Sentiment Indicator considers price action and recent trends in volume. Increasing volumes often mean that a trend is strengthening, while decreasing volumes can signal that a reversal could come soon. The options market is another place to get signals about sentiment. Since options allow investors to place bets on the price of a stock, we consider the ratio of calls and puts for stocks where options are available.

What's Happening With TTNP Stock Today?

Titan Pharmaceuticals, Inc. common stock (TTNP) stock is trading at $0.90 as of 12:48 PM on Thursday, Dec 15, a drop of -$0.06, or -6.62% from the previous closing price of $0.96. The stock has traded between $0.88 and $1.00 so far today. Volume today is above average. So far 182,901 shares have traded compared to average volume of 29,909 shares. To screen for more stocks like Titan Pharmaceuticals, Inc. common stock click here.

More About Titan Pharmaceuticals, Inc. common stock

Titan Pharmaceuticals Inc is a pharmaceutical company developing therapeutics utilizing its proprietary long-term drug delivery platform, ProNeura, for the treatment of select chronic diseases for which steady state delivery of a drug provides efficacy and/or safety benefit. ProNeura consists of a small, solid implant made from a mixture of ethylene-vinyl acetate, or EVA, and a drug substance. Its first product based on ProNeura technology was the Probuphine (buprenorphine) implant, which was approved in the United States, Canada and the European Union, for the maintenance treatment of opioid use disorder in clinically stable patients taking 8 mg or less a day of oral buprenorphine. Click Here to get the full Stock Report for Titan Pharmaceuticals, Inc. common stock stock.